Efficacy of cinacalcet in hyperparathyroidism after renal transplantation.

The efficacy of the calcimimetic Cinacalcet in persistent Hyperparathyroidsm After Renal Transplantation. A sustained or temporary effect?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON24309

Enrollment

Registered

2006-01-31

Start date

2006-02-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

open label observational study during 8 months in approx 20 renal transplant patients

Interventions

Administration of start dose of 30 mg cinacalcet when inclusion criteria are met. Weekly and later monthly monitoring of biochemical and clinical parameters. Six month after inclusion and reaching sta

Eligibility

Inclusion criteria

Inclusion criteria: 1. Hypercalciemia more than 2,60 mmol/l; 2. Elevated iPTH plasma levels more than 15 pmol/l; 3. Renaltranplantion longer than 2 months and stable renal function for at least 2 weeks; 4. Older than 18 years; 5. No vit D deficiency.

Exclusion criteria

Exclusion criteria: 1. Antirejection therapy less than 4 weeks; prior to inclusion; 2. Pregnancy.

Design outcomes

Primary

Measure	Time frame
Normalisation of serum calcium and parathormon at six months.	—

Secondary

Measure	Time frame
Reduced and sustained parathormon activity after withdrawal of cinacalcet.	—

Contacts

Public ContactS. Surachno

Academic Medical Center (AMC), Renal transplant unit, P.O. Box 22660

s.surachno@amc.uva.nl+31 (0)20 5664170 / +31 (0)20 5669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)